Australia markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
44.96-0.24 (-0.53%)
At close: 04:00PM EDT
44.50 -0.46 (-1.02%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close45.20
Open44.75
Bid44.89 x 200
Ask45.42 x 100
Day's range41.62 - 45.74
52-week range3.03 - 50.42
Volume147,992
Avg. volume282,995
Market cap480.474M
Beta (5Y monthly)2.47
PE ratio (TTM)N/A
EPS (TTM)-6.90
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est71.00
  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

    NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresentation

  • GlobeNewswire

    Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended Mar

  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

    NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024. Details of the panel discussion are as follow: BTIG Obesity Health ForumPanel Title: CB1 Axis Therapies for ObesityDate: Wednesday, May 8, 2024Presentation Time: 3:00 p.m. ET